Search
Showing results for "8"
Managing blood glucose levels with different foods can be challenging. Our research team would like to know how the hybrid closed loop system, deals with these foods, compared to standard pump therapy.
Identifying pediatric lung disease: A comparison of forced oscillation technique outcomes Abstract Rationale Increasing evidence suggests the forced
As a not-for profit child health research organisation we rely on the generosity of our partners, communities and supporters to improve the health, development and lives of children through excellence in research.
Your generosity creates a significant impact on our research and on the lives of children everywhere
Amy Penelope Yael Finlay-Jones Strauss Perry BPsych(Hons), MPsych(Clinical), MHealthEcon, PhD (Clin Psych) BA, MPH, PhD BPsych (Hons) MPsych (Clin)
Our popular workshops for kids are back these school holidays and we have a jam-packed program full of fun and engaging science activities!
Promoting wellbeing for youth is a global health priority and young people with chronic conditions demonstrate disproportionately low wellbeing compared to their peers. However, wellbeing is variably defined, and little is understood as to what wellbeing means for this population. The aim of this study was to develop a conceptualisation of wellbeing that is rooted in the perspectives of young people with chronic conditions.
The airway epithelium is the primary structural and functional airway barrier and orchestrates innate immunity. Some children may have underlying epithelial vulnerabilities that contribute to the pathogenesis of acute wheeze and asthma.
Tools that can be used to collect behavioural data during pandemics are needed to inform policy and practice. The objective of this project was to develop the Your COVID-19 Risk tool in response to the global spread of COVID-19, aiming to promote health behaviour change. We developed an online resource based on key behavioural evidence-based risk factors related to contracting and spreading COVID-19. This tool allows for assessing risk and provides instant support to protect individuals from infection.
Nirsevimab is a long-acting monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection in infants and high-risk children. During the 2024 RSV season in Western Australia, 21 922 doses were administered to infants entering their first season and 1221 doses to at-risk children. In this context, the selection and spread of escape variants are a potential concern. This study aimed to investigate nirsevimab binding site mutations using clinical and wastewater data.